MTB
65
-3
PEP
53
3
NWS
60
2
EL
30
-4
TROW
59
-3
PGR
67
2
STI
19
-12
XRAY
46
2
ORLY
64
-2
EQT
44
-6
HRL
51
4
HP
52
2
JWN
48
2
BLK
55
-2
XYL
52
5
PM
66
2
PSX
49
2
SJM
19
-12
DRI
60
2
TGT
31
4
MTB
65
-3
PEP
53
3
NWS
60
2
EL
30
-4
TROW
59
-3
PGR
67
2
STI
19
-12
XRAY
46
2
ORLY
64
-2
EQT
44
-6
HRL
51
4
HP
52
2
JWN
48
2
BLK
55
-2
XYL
52
5
PM
66
2
PSX
49
2
SJM
19
-12
DRI
60
2
TGT
31
4
Financhill
Back

Matinas BioPharma Holdings Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
38

MTNB
Matinas BioPharma Holdings

Last Price:
0.64
Seasonality Move:
9.18%

7 Day Trial

ALL ACCESS PASS

$ 7

Matinas BioPharma Holdings Price Quote

$0.64
0.00 (1.8%)
(Updated: November 30, 2024 at 5:48 AM ET)

Matinas BioPharma Holdings Key Stats

Sell
38
Matinas BioPharma Holdings (MTNB) is a Sell
Day range:
$0.61 - $0.66
52-week range:
$0.50 - $21.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.70
P/B ratio:
0.21%
Volume:
10.6K
Avg. volume:
397.2K
1-year change:
-93.57%
Market cap:
$3.3M
Revenue:
$1.1M
EPS:
$-4.79

How Much Does Matinas BioPharma Holdings Make?

Data Unavailable

Is Matinas BioPharma Holdings Growing As A Company?

Data Unavailable

Matinas BioPharma Holdings Stock Price Performance

What Is Matinas BioPharma Holdings 52-Week High & Low?

Matinas BioPharma Holdings Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Matinas BioPharma Holdings?

Is Matinas BioPharma Holdings Cash Flow Positive?

  • What Is MTNB Cash Flow From Operations?
    Cash flow from operations (TTM) is -$17M
  • What Is Matinas BioPharma Holdings’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $9.2M
  • What Is Matinas BioPharma Holdings’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $11.7M

Matinas BioPharma Holdings Return On Invested Capital

Data Unavailable

Matinas BioPharma Holdings Earnings Date & Stock Price

Matinas BioPharma Holdings Competitors

Matinas BioPharma Holdings Dividend Yield

Matinas BioPharma Holdings Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 19.43%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 30.00
Upside from Last Price: 4565.63%

Major Shareholders

  • How many MTNB shares are owned by institutional investors?
    4.9M MTNB shares are owned by institutional investors
  • How many MTNB shares are owned by insiders?
    11.3M MTNB shares are owned by insiders